Scientist behind Alzheimer’s drug in late-stage trials is indicted on charges of research fraud. The charges are related to alleged fabrication of research images and data that Hoau-Yan Wang may have used to secure federal grants from the National Institutes of Health (Jun 2024) Article

[Michael Harrop]

https://www.nbcnews.com/science/science-news/scientist-alzheimers-drug-candidate-indicted-charges-research-fraud-rcna159537

The Summary​

• A neuroscientist whose work helped pave the way for an Alzheimer’s drug candidate was indicted on charges of fraud.
• The charges are related to the alleged fabrication of research images and data that the scientist may have used to secure grants.
• The manipulation of research images is a growing concern in the scientific community.

Click to shrink...

Wang, a medical professor at the City University of New York, collaborated with Cassava Sciences, a pharmaceutical company based in Austin, Texas, as it investigated an Alzheimer’s drug candidate called simufilam. He was awarded some $16 million in grants for early-stage drug development in collaboration with Cassava, according to the indictment.

In 2023, he told The Wall Street Journal that a CUNY investigation made “no conclusive findings of data manipulation, consistent with what I’ve been saying for two years.”

Multiple journal articles on which Wang was an author have been retracted, according to the website Retraction Watch.

Click to shrink...